1.Endoscopic Ultrasound-Guided Fine Needle Aspiration Using a 22-G Needle for Hepatic Lesions: Single-Center Experience
Ebru AKAY ; Deniz ATASOY ; Engin ALTINKAYA ; Ali KOÇ ; Tamer ERTAN ; Hatice KARAMAN ; Erkan CAGLAR
Clinical Endoscopy 2021;54(3):404-412
Background/Aims:
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has been accepted as a reliable tool in diagnosing and staging intra-abdominal tumors. In this study, we aimed to investigate the performance of EUS-FNA in the evaluation of liver masses and its impact on patient management and procedure-related complications retrospectively.
Methods:
Data of patients who underwent EUS-FNA biopsies due to liver masses between November 2017 and July 2018 were retrieved retrospectively. Biopsies were performed using 22-G needles. The demographics, EUS-FNA results, sensitivity and specificity of the procedure, negative predictive value, positive predictive value, and specimen sufficiency rates were assessed.
Results:
A total of 25 patients (10 females) were included in the study. The mean age was 62.73±15.2 years. The mean size of the masses was 34.50±16.04 mm. The technical success rate was 88%. During the EUS-FNA procedure, each patient had only one pass with 94.45% of aspirate sufficiency rate and 86.3% of biopsy sufficiency rate. The diagnostic accuracy rate was 86.3%. There were no complications.
Conclusions
For the evaluation of liver masses, EUS-FNA using a 22-G needle with even one pass had high aspiration and biopsy success rates accompanied with high diagnostic accuracy rates.
2.Endoscopic Ultrasound-Guided Fine Needle Aspiration Using a 22-G Needle for Hepatic Lesions: Single-Center Experience
Ebru AKAY ; Deniz ATASOY ; Engin ALTINKAYA ; Ali KOÇ ; Tamer ERTAN ; Hatice KARAMAN ; Erkan CAGLAR
Clinical Endoscopy 2021;54(3):404-412
Background/Aims:
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has been accepted as a reliable tool in diagnosing and staging intra-abdominal tumors. In this study, we aimed to investigate the performance of EUS-FNA in the evaluation of liver masses and its impact on patient management and procedure-related complications retrospectively.
Methods:
Data of patients who underwent EUS-FNA biopsies due to liver masses between November 2017 and July 2018 were retrieved retrospectively. Biopsies were performed using 22-G needles. The demographics, EUS-FNA results, sensitivity and specificity of the procedure, negative predictive value, positive predictive value, and specimen sufficiency rates were assessed.
Results:
A total of 25 patients (10 females) were included in the study. The mean age was 62.73±15.2 years. The mean size of the masses was 34.50±16.04 mm. The technical success rate was 88%. During the EUS-FNA procedure, each patient had only one pass with 94.45% of aspirate sufficiency rate and 86.3% of biopsy sufficiency rate. The diagnostic accuracy rate was 86.3%. There were no complications.
Conclusions
For the evaluation of liver masses, EUS-FNA using a 22-G needle with even one pass had high aspiration and biopsy success rates accompanied with high diagnostic accuracy rates.
3.Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study
Okan OKTAR ; Vakkas KORKMAZ ; Alp TOKALIOĞLU ; Çağatayhan ÖZTÜRK ; Özgür ERDOĞAN ; Yeşim UÇAR ; Hande Esra KOCA YILDIRIM ; Candost HANEDAN ; Fatih KILIÇ ; Burak ERSAK ; Necim YALÇIN ; Fatma ÖZMEN ; Alper KAHRAMAN ; Selin Aktürk ESEN ; Sevda BAŞ ; Emel Doğan ÖZDAŞ ; İlker SELÇUK ; Gökhan UÇAR ; Özgür KOÇAK ; Caner ÇAKIR ; Sevgi KOÇ ; Çiğdem KILIÇ ; Günsu Kimyon CÖMERT ; Işın ÜREYEN ; Tayfun TOPTAŞ ; Mehmet Ali NARIN ; Tolga TAŞÇI ; Salih TAŞKIN ; Nurettin BORAN ; Muzaffer SANCI ; Fahriye Tuğba KÖŞ ; Özlem Moraloğlu TEKIN ; Yaprak Engin ÜSTÜN ; Fırat ORTAÇ ; Taner TURAN
Journal of Gynecologic Oncology 2024;35(3):e39-
Objective:
To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT).
Methods:
A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study.
Results:
The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased.
Conclusion
In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.
4.Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study
Okan OKTAR ; Vakkas KORKMAZ ; Alp TOKALIOĞLU ; Çağatayhan ÖZTÜRK ; Özgür ERDOĞAN ; Yeşim UÇAR ; Hande Esra KOCA YILDIRIM ; Candost HANEDAN ; Fatih KILIÇ ; Burak ERSAK ; Necim YALÇIN ; Fatma ÖZMEN ; Alper KAHRAMAN ; Selin Aktürk ESEN ; Sevda BAŞ ; Emel Doğan ÖZDAŞ ; İlker SELÇUK ; Gökhan UÇAR ; Özgür KOÇAK ; Caner ÇAKIR ; Sevgi KOÇ ; Çiğdem KILIÇ ; Günsu Kimyon CÖMERT ; Işın ÜREYEN ; Tayfun TOPTAŞ ; Mehmet Ali NARIN ; Tolga TAŞÇI ; Salih TAŞKIN ; Nurettin BORAN ; Muzaffer SANCI ; Fahriye Tuğba KÖŞ ; Özlem Moraloğlu TEKIN ; Yaprak Engin ÜSTÜN ; Fırat ORTAÇ ; Taner TURAN
Journal of Gynecologic Oncology 2024;35(3):e39-
Objective:
To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT).
Methods:
A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study.
Results:
The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased.
Conclusion
In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.
5.Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study
Okan OKTAR ; Vakkas KORKMAZ ; Alp TOKALIOĞLU ; Çağatayhan ÖZTÜRK ; Özgür ERDOĞAN ; Yeşim UÇAR ; Hande Esra KOCA YILDIRIM ; Candost HANEDAN ; Fatih KILIÇ ; Burak ERSAK ; Necim YALÇIN ; Fatma ÖZMEN ; Alper KAHRAMAN ; Selin Aktürk ESEN ; Sevda BAŞ ; Emel Doğan ÖZDAŞ ; İlker SELÇUK ; Gökhan UÇAR ; Özgür KOÇAK ; Caner ÇAKIR ; Sevgi KOÇ ; Çiğdem KILIÇ ; Günsu Kimyon CÖMERT ; Işın ÜREYEN ; Tayfun TOPTAŞ ; Mehmet Ali NARIN ; Tolga TAŞÇI ; Salih TAŞKIN ; Nurettin BORAN ; Muzaffer SANCI ; Fahriye Tuğba KÖŞ ; Özlem Moraloğlu TEKIN ; Yaprak Engin ÜSTÜN ; Fırat ORTAÇ ; Taner TURAN
Journal of Gynecologic Oncology 2024;35(3):e39-
Objective:
To define the clinical, histopathological features and the prognostic factors affecting survival in patients with adult granulosa cell tumors of the ovary (AGCT).
Methods:
A 322 patients whose final pathologic outcome was AGCT treated at nine tertiary oncology centers between 1988 and 2021 participated in the study.
Results:
The mean age of the patients was 51.3±11.8 years and ranged from 21 to 82 years.According to the International Federation of Gynecology and Obstetrics 2014, 250 (77.6%) patients were stage I, 24 (7.5%) patients were stage II, 20 (6.2%) patients were stage III, and 3 (7.8%) were stage IV. Lymphadenectomy was added to the surgical procedure in 210(65.2%) patients. Lymph node involvement was noted in seven (3.3%) patients. Peritoneal cytology was positive in 19 (5.9%) patients, and 13 (4%) had metastases in the omentum. Of 285 patients who underwent hysterectomy, 19 (6.7%) had complex hyperplasia with atypia/ endometrial intraepithelial neoplasia, and 8 (2.8%) had grade 1 endometrioid endometrial carcinoma. It was found that 93 (28.9%) patients in the study group received adjuvant treatment. Bleomycin, etoposide, cisplatin was the most commonly used chemotherapy protocol. The median follow-up time of the study group was 41 months (range, 1–276months). It was noted that 34 (10.6%) patients relapsed during this period, and 9 (2.8%)patients died because of the disease. The entire cohort had a 5-year disease-free survival (DFS) of 86% and a 5-year disease-specific survival of 98%. Recurrences were observed only in the pelvis in 13 patients and the extra-abdominal region in 7 patients. The recurrence rate increased 6.168-fold in patients with positive peritoneal cytology (95% confidence interval [CI]=1.914–19.878; p=0.002), 3.755-fold in stage II–IV (95% CI=1.275–11.063; p=0.016), and 2.517-fold in postmenopausal women (95% CI=1.017–6.233; p=0.046) increased.
Conclusion
In this study, lymph node involvement was detected in 3.3% of patients with AGCT. Therefore, it was concluded that lymphadenectomy can be avoided in primary surgical treatment. Positive peritoneal cytology, stage, and menopausal status were independent prognostic predictors of DFS.